These findings suggest that while BRAF-mutated melanoma cells exhibit the highest sensitivity to ML00253764, the compound also exerts notable inhibitory effects in colorectal and anaplastic thyroid cancer models, reinforcing its potential as a therapeutic agent for multiple tumor types. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.